throbber
From:
`Sent:
`To:
`CC:
`
`Subject:
`
`cara lansdeulcarnbridgelbiogen;nsf;cara.lansden@biogenidec.corn;srnlp
`Thu Jul 06 2006 13:11:08 EDT
`minima yang/cambridgelbiogen@biogenidec;
`gilmore o'neillicambridgelbiogen@biogenidec;
`lingamaneni/cambridgelbiogen@biogenidec;
`Re: BG-12 MS COT meeting minutes
`
`;ratna
`
`.Minhua Yang/Cambridge/Biogen
`07/06/2006 10:47 AM
`Message Size: 74.0 KB
`
`To
`Cara Lansden/Cambridge/Biogen@Biogenldec
`cc
`Gilmore O'Neill/Cambridge/Biogen@Biogenldec, Ratna
`Lingamaneni/Cambridge!Biogen@Biogenldec,
`Subject
`Re: BG-12 MS CDT meeting minutes
`
`Hi Cara:
`
`I j ust read the minutes from yesterday and have a comment. I sent out an email in June to you
`
`Page 1 of6
`
`Biogeo Exhibit 2316
`Coalition v. Biogeo
`IPR2015-01993
`
`

`

`about the revised sample size if 480 mg am1 is added, the sample size for both studies will be
`changed. Please see below.
`
`Thanks. -minhua
`
`Putpose:
`
`Calculate the additional patients needed if a 480mg dosing ann needs to be added to the Phase 3
`protocols.
`
`Assumptions:
`For both the placebo-controlled trial and the 3-atm trial, adding an additional arm means that we
`will need to adjust for multiple comparisons (i.e., we are doing the statistical comparisons more
`than once, 720 mg vs placebo, 480 mg vs placebo, and additionally, Cop vs placebo). If we use a
`closed testing procedure, and the do the testing in a "step-wise" fashion, then the test of 720 mg
`vs placebo first, if that is statistically significant at the 0.05 level, then test the 480 mg vs placebo
`second, at the alpha = 0.05 leveL However, this assumes, that if the 720 mg does not work, then
`we WON'T test the 480 mg vs placebo, i.e., that comparison is declared statistically not
`significant, whether or not it really is. I have discussed with Cara and, since we think this
`scenario is unlikely, we will accept the risk, and will use the closed testing procedure for
`multiple comparison adjustment This way, both comparisons will be done at the 0.05 level.
`
`New sample size:
`
`1. Placebo controlled ttial, 1:1:1 randomization, placebo: 720 mg/day : 480 mg/day. It will be
`350:350:350 patients, total of 1050. A drop out rate of 20% over 2-years is assumed.
`
`2. 4-atm trial, 1:1:1: I randomization, placebo: 720 mg/day: 480 mg/day: Copaxone. It will be
`350:350:350: 350, patients, total of 1400. A drop out rate of20% over 2-years is assumed.
`
`-minhua
`
`Cara Lansden/Camb1idge/Biogen
`07/05/2006 03:27PM
`Message Size: 70.2 KB
`
`Page 2 of6
`
`

`

`To
`Gilmore O'Neill/Cambridge/Biogen@Biogenidec, Kate
`Dawson/Camb1idge/Biogen@Biogenldec, Minhua Yang/Cambridge/Biogen@Biogenidec
`cc
`
`BG- 12 MS CDT meeting minutes
`
`Tammy Samelli/Cambridge/Biogen@Biogenldec
`
`Hi all :
`
`Attached are the minutes from this rooming's BG-12 MS CDT. Please let me know if you have
`any questions.
`
`Starting next week, 12 July, -
`
`will be leading the CDT.
`
`Today was my last BG-12 CDT and it has been a great expe1ience working with you all. You
`have been a fabulous team, and I learned so much as we faced and overcame each challenge in
`the BG-12 MS clinical program together. It was never a dull moment with BG-12! Now, I leave
`and I am confident that the BG- 12 team will continue to be a
`you in good hands with -
`trailblazer in the MS world.
`
`Regards,
`Cara
`
`Page 3 of6
`
`

`

`Cara Lansden
`Sr. Manager, Clinical Development
`Biogeo Idee
`Tel +617-679-2658
`Fax +617-679-3518
`Email: cara.lansden@biogenidec.com
`
`Page 4 of6
`
`

`

`BG-12 MS
`Clinical Development Team
`Subject: Minutes from BG-12 MS CDT meeting on 05 July 2006
`Date:
`05 July 2006
`
`Attendees: Cara Lansden, Gilmore O’Neill, Kate Dawson, Tammy Sarnelli,
`
`
`
`Kate Dawson will be the new MD for the BG-12 MS program.
`The transition between G. O’Neill and K. Dawson is in progress, but the final date
`of the complete transition is still undefined.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1
`
`Introduction of Kate Dawson
`
`2 National Scientific Advice
`feedback from UK and Spain
`
`
`
`
`
`
`.Spain:
`
`
`
`UK:
`
`3 EOP2 Meeting – Timing and
`Prep Activities
`
`
`
`
`
`
`
`Protocol:
`o
`
`Protocol updates are ongoing – VPs will all review during C. Bozic’s
`review cycle.
`
`EOP2 Package:
`o
`Needs more emphasis on the unmet need.
`
`
`
`
`
`
`
`Timelines:
`o
`o
`o
`
`FDA has until Friday, 07 July to inform BIIB of the EOP2 meeting
`date.
`The meeting is likely to be scheduled for the 3rd or 4th week in August,
`even possibly in September.
`Once a meeting date is set, then the team will meet again to discuss
`timing of final revisions to the EOP2 package, as well as impact to
`
`Page 1/2
`
`Page 5 of 6
`
`

`

`4 AOB
`
`
`
`BG-12 MS
`Clinical Development Team
`timing of FPI.
`o
`There will not be a presentation, though BIIB will have slides
`o
`The meeting will be 1-1.5 hours in length.
`A country selection meeting was held on Friday, 30 June with Global Commercial.
`For the majority of countries, there was agreement between Clinical and
`Commercial on their prioritization. There were a few countries that Commercial
`would like to include and will provide potential investigators for Clinical to evaluate
`as possible study sites, either for the 2 Phase 3 pivotal studies or other studies in the
`Phase 3 program.
`
`Action Items:
`1 Calculate the additional patients needed if a 480mg dosing arm
`needs to be added to the Phase 3 protocols.
`
`Assigned To:
`M. Yang
`
`Date Due:
`ASAP
`
`2
`
`Provide data on MS incidence and approved therapies in Brazil for
`consideration as a potential country to include in Phase 3
`
`C. Hoffman
`
`ASAP
`
`Status:
`Completed:
`109-MS-301
`remains the same
`but 109-MS-302
`sample size
`becomes 1200
`New
`
`Page 2/2
`
`Page 6 of 6
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket